# Gilead Sciences Inc. (GILD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $151.00, market value $187.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Gilead Sciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.01**. A PEG of 0.01 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 6.1×**. Each dollar of revenue is priced at 6.1×.
- **Price / book: 15.8×**. The shares trade at 15.8× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 6.9%** (5-yr avg 9.2%). Free cash flow equals 6.9% of the market value, below its five-year average of 9.2%, so the shares are pricier on cash than usual. Above 5% is generally attractive.

## Profitability
- **Operating margin: -8.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: 28.9%**. 28.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 37.5%**. 37.5% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: -4.1%**. Return on all capital, debt included, is -4.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -5.5%**. Each dollar of assets produces -5.5% of profit.

## Growth
- **Revenue growth (1 yr): 2.4%** (3-yr 2.6%/yr, 5-yr 3.6%/yr). Revenue grew 2.4% over the last year, against 3.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 1684.2%** (3-yr 23.0%/yr, 5-yr 132.4%/yr). Earnings per share rose 1684.2%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 4.3%/yr**. Free cash flow has compounded at 4.3% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 1.10**. Debt is 1.10 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Current ratio: 1.55** (quick 1.55). Current assets cover the next year's liabilities 1.55 times.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 2.17%** ($3.22 per share, trailing). Gilead Sciences Inc. yields 2.17%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 47%** (31% of free cash flow). 47% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 11**. 11 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 3.0%/yr** (1-yr 2.6%). The dividend has grown 3.0% a year over five years.

## Analyst view
- **Analyst consensus: buy** (27 analysts). 27 analysts cover Gilead Sciences Inc.; the consensus is buy, with an average price target of $157.41 (+4% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 37.4%** (YTD 24.5%, 3-mo 17.7%). The shares are up 37.4% over twelve months including dividends.
- **From 52-week high: -4.0%** (39.2% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 68**. An RSI of 68 is neutral.
- **Beta (1 yr): 0.37** (volatility 27%). Beta of 0.37 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GILD · Page: https://foliofundamentals.com/stocks/gild

Not investment advice.